In a significant legal challenge, pharmaceutical giant Eli Lilly has petitioned the U.S. Supreme Court to declare the whistleblower provisions of the False Claims Act (FCA) as unconstitutional. This move comes in the wake of the Seventh Circuit Court’s decision to uphold a $183 million judgment in favor of a whistleblower who accused the company of misrepresenting drug prices to Medicaid.
Eli Lilly’s argument centers on the contention that the qui tam provisions, which allow private individuals to sue on behalf of the government, infringe upon the executive branch’s authority. The company argues that these provisions unconstitutionally delegate prosecutorial power to private individuals without appropriate executive oversight. The full details are reported in Law360.
This legal dispute has far-reaching implications, with the potential to impact not only the pharmaceutical industry but also various sectors where the FCA is frequently invoked. Historically, the Supreme Court has upheld the FCA, considering it a vital tool for uncovering fraud against the government. However, corporations have increasingly questioned its scope, especially the empowerment of whistleblowers with vested interests.
The FCA, enacted during the Civil War era, aimed to combat fraud by defense contractors. Over time, it has evolved into a significant enforcement mechanism, with the government recovering billions of dollars through settlements and judgments each year. The current case against Eli Lilly could redefine the balance between private whistleblowers and government prosecutorial power.
Several legal scholars and industry groups have taken an interest in this case. The crux of the debate is whether allowing private individuals to pursue FCA claims undermines the separation of powers doctrine. If the Supreme Court sides with Eli Lilly, it could lead to a major shift in how fraud cases are prosecuted under the FCA.
This ongoing legal battle underscores ongoing tensions in the use of the FCA. As corporations navigate complex regulatory environments, the outcome of Eli Lilly’s appeal may suggest a recalibration of the legal frameworks shaping corporate accountability and governmental oversight.